Skip to main content
. Author manuscript; available in PMC: 2011 May 25.
Published in final edited form as: Nature. 2010 Nov 25;468(7323):567–571. doi: 10.1038/nature09526

Figure 1. Heterogeneous therapeutic impact of p53 restoration in KrasG12D driven lung tumours.

Figure 1

a. Schematic representation of the experimental treatment regime. KrasG12D was activated in the lung epithelium of 8 week old KR;p53KI/KI mice by adenoviral-Cre nasal inhalation and the resulting tumours treated with Tam or vehicle (Ctrl) 15 weeks after adenoviral infection.

b. Haematoxylin and Eosin staining of lung sections from KR;p53KI/KI mice showing tumour load after 7 daily control (Ctrl) or Tam treatments.

c. Quantification of Ki67 positive cells per lung tumour from 7 day Tam/Ctrl-treated KR;p53KI/KI mice. Error bars indicate standard error of mean (Ctrl: s.e.m=1.20 n=55; Tam: s.e.m=1.31 n=37). * P=0.0003, Student’s t-test.

d. Percent of apoptotic (TUNEL-positive) tumours (scored as a minimum of 1 positive cell per tumour section) in 7 day Ctrl and Tam treated KR;p53KI/KI lungs (n=37 Ctrl; n=22 Tam treated tumours). * P=0.0064, Pearson Chi square.

e. KR;p53KI/KI lung tumours from KR;p53KI/KI treated for 6 hrs with Tam, showing either no discernible TUNEL staining (Neg) or significant levels of TUNEL staining (Pos). Scale bar=100 µm.